Frequency Therapeutics is pioneering a new category in regenerative medicine. Frequency’s progenitor cell activation platform aims to restore human function by developing therapeutics that activate a person’s innate regenerative potential within the body. The Company’s lead preclinical program is designed to activate oligodendrocyte precursor cells with the goal of driving remyelination and potential functional recovery for individuals living with multiple sclerosis.